Company: MDCXW
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0001062993-25-008246
Chunk: 12

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 12
---
 material interest. Where appropriate, directors will abstain from portions of board or committee meetings to allow independent discussion of points in issue. We intend to disclose any amendments to or waivers of certain provisions of our Code of Conduct and Ethics in a Current Report on Form 8-K. The Code is available on our corporate website at www.medicuspharma.com/corporate-govenance/. Corporate Governance Nominating Committee The primary function of the Nominating Committee, in accordance with its charter, is to assist the Board in fulfilling its responsibility to oversee our nominating procedures. The Nominating Committee is required to review and assess the adequacy of its charter periodically as conditions dictate, but at least annually, to ensure compliance with any rules or regulations and recommend any modifications to its charter if and when appropriate to the Board for its approval. Nominating Committee Charter The Board has adopted a written charter for the Nominating Committee, which sets out the Nominating Committee's responsibilities, including; making recommendations to the Board with respect to the size, composition and structure of the Board; making recommendations to the Board with respect to the reorganization of responsibilities among committees, the creation of additional committees or subcommittees, or the elimination of committees; making recommendations to the Board with respect to the preferred experience and qualifications of new directors to be elected by shareholders; 8 making recommendations to the Board with respect to qualified candidates for nomination for election to the Board at each annual general meeting of shareholders; making recommendations to the Board with respect to the appointment of qualified directors to each committee; making recommendations to the Board with respect to developing and overseeing an orientation program for new directors and a continuing education program for current directors; making recommendations to the Board with respect to Board succession; and conducting annual performance assessments of the Board. A copy of the Nominating Committee Charter is available on our corporate website at www.medicuspharma.com/corporate-govenance/. Audit Committee Composition of the Audit Committee Our Audit Committee is currently comprised of four members. Each member of our Audit Committee is a non-employee member of our Board. In addition, each member of our Audit Committee is financially literate, as required by the Nasdaq Rules and Canadian securities laws and our board of directors has determined that Robert J. Ciaruffoli qualifies as an "audit committee financial expert" as defined in applicable SEC rules. All of the members of our Audit Committee are "independent" members of our Board, as required by the Nasdaq Rules, Rule 10A